Studies that include patients who are considered at-risk (i.e., diabetics, cardiac, elderly, etc.) and are currently taking GLP-1 RAs should also be performed as these patients may have compounding risk during the perioperative period which may make them more susceptible to complications related to GLP-1 use (Santos et al
Work with your provider to submit any additional supporting documentation
Soeung, M, Yan, X, Zanca, C, Qian, J, Karki, M, Duan, F, Khan, H, Zhang, L, Peng, D, Williams, M, He, R, Chen, Z, Perelli, L, Chen, J, Tidwell, R, Chauhan, PK, Le, C, Lam, TA, Bhattacharya, N, Shah, R, Ho, IL, Gay, J, Carrillo, CC, Feng, N, Le, K, Gao, G, Perry, TL, Mseeh, F, Jiang, Y, Xu, Q, Zacharias, NM, Sheth, RA, Bathala, TK, Rao, P, Daw Bitar, N, Tripathi, DN, Walker, CL, Mohammad, MM, Zhang, J, Han, G, Chu, Y, Wang, R, Dang, M, Dai, E, Peng, F, Liu, Y, Jadhav, A, Lang, W, Arrechedera, C, Clemente, LC, Parra Cuentas, ER, Lu, H, Haymaker, CL, Wistuba, II, Futreal, A, Viale, A, Soth, MJ, Jones, PH, Marszalek, JR, Heffernan, TP, Draetta, G, Tannir, NM, Gao, J, Wang, L , Genovese, G, Msaouel, P
To date, all these peptides have followed similar trajectories: promising animal data with no evidence of efficacy in humans, despite extensive advertising and widespread availability of these compounds to athletes, Ellis and colleagues wrote in their AOSSM article
